372 related articles for article (PubMed ID: 18032739)
1. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II).
Adams HP; Effron MB; Torner J; Dávalos A; Frayne J; Teal P; Leclerc J; Oemar B; Padgett L; Barnathan ES; Hacke W;
Stroke; 2008 Jan; 39(1):87-99. PubMed ID: 18032739
[TBL] [Abstract][Full Text] [Related]
2. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial.
Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators
Stroke; 2005 Apr; 36(4):880-90. PubMed ID: 15731473
[TBL] [Abstract][Full Text] [Related]
3. Treating patients with 'wake-up' stroke: the experience of the AbESTT-II trial.
Adams HP; Leira EC; Torner JC; Barnathan E; Padgett L; Effron MB; Hacke W;
Stroke; 2008 Dec; 39(12):3277-82. PubMed ID: 18772451
[TBL] [Abstract][Full Text] [Related]
4. Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study.
Abciximab in Ischemic Stroke Investigators
Stroke; 2000 Mar; 31(3):601-9. PubMed ID: 10700492
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.
Qureshi AI; Harris-Lane P; Kirmani JF; Janjua N; Divani AA; Mohammad YM; Suarez JI; Montgomery MO
Neurosurgery; 2006 Oct; 59(4):789-96; discussion 796-7. PubMed ID: 16915119
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
[TBL] [Abstract][Full Text] [Related]
7. MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window.
Mitsias PD; Lu M; Silver B; Morris D; Ewing JR; Daley S; Lewandowski C; Katramados A; Papamitsakis NI; Ebadian HB; Zhao Q; Soltanian-Zadeh H; Hearshen D; Patel SC; Chopp M
Neurology; 2005 Aug; 65(4):612-5. PubMed ID: 16116128
[TBL] [Abstract][Full Text] [Related]
8. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
Clark WM; Albers GW; Madden KP; Hamilton S
Stroke; 2000 Apr; 31(4):811-6. PubMed ID: 10753980
[TBL] [Abstract][Full Text] [Related]
9. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
10. Results of Membrane-Activated Chelator Stroke Intervention randomized trial of DP-b99 in acute ischemic stroke.
Lees KR; Bornstein N; Diener HC; Gorelick PB; Rosenberg G; Shuaib A;
Stroke; 2013 Mar; 44(3):580-4. PubMed ID: 23391764
[TBL] [Abstract][Full Text] [Related]
11. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
[TBL] [Abstract][Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
13. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
[TBL] [Abstract][Full Text] [Related]
14. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.
Lee DH; Jo KD; Kim HG; Choi SJ; Jung SM; Ryu DS; Park MS
J Vasc Interv Radiol; 2002 Aug; 13(8):769-74. PubMed ID: 12171979
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab.
Morris DC; Silver B; Mitsias P; Lewandowski C; Patel S; Daley S; Zhang ZG; Lu M
Acad Emerg Med; 2003 Dec; 10(12):1396-9. PubMed ID: 14644794
[TBL] [Abstract][Full Text] [Related]
16. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Déry JP; Proulx G; Roy L; Poirier P; Costerousse O; De Larochellière R
Int J Cardiol; 2009 Aug; 136(2):165-70. PubMed ID: 18656274
[TBL] [Abstract][Full Text] [Related]
17. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study.
Eckert B; Koch C; Thomalla G; Kucinski T; Grzyska U; Roether J; Alfke K; Jansen O; Zeumer H
Stroke; 2005 Jun; 36(6):1160-5. PubMed ID: 15890988
[TBL] [Abstract][Full Text] [Related]
18. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
Furlan AJ; Eyding D; Albers GW; Al-Rawi Y; Lees KR; Rowley HA; Sachara C; Soehngen M; Warach S; Hacke W;
Stroke; 2006 May; 37(5):1227-31. PubMed ID: 16574922
[TBL] [Abstract][Full Text] [Related]
19. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z;
Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884
[TBL] [Abstract][Full Text] [Related]
20. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
